SCHEMBL3406473

SCHEMBL3406473

O=C(Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1)NC1CCN(CCC(F)(F)F)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 5/20 0.47
CYP2D6 P10635 1/20 0.41
EPHX2 P34913 2/20 0.40
DCUN1D1 Q96GG9 6/20 0.40
UBE2M P61081 4/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109188 0.92 CXCR3 (0.44) CXCR3CYP2D6EPHX2DCUN1D1UBE2M
SCHEMBL3408501 0.91 CXCR3 (0.49) CXCR3CYP2D6EPHX2DCUN1D1UBE2M
SCHEMBL3414458 0.91 CXCR3 (0.49) CXCR3CYP2D6EPHX2KMT2AMEN1
SCHEMBL3408455 0.88 EPHX2 (0.46) CXCR3CYP2D6EPHX2KMT2AMEN1
SCHEMBL3415823 0.88 EPHX2 (0.51) CXCR3EPHX2
SCHEMBL3408431 0.88 CXCR3 (0.47) CXCR3CYP2D6EPHX2DCUN1D1KMT2A
SCHEMBL3408559 0.88 CXCR3 (0.47) CXCR3CYP2D6EPHX2KMT2AMEN1
SCHEMBL3410345 0.87 CXCR3 (0.46) CXCR3CYP2D6EPHX2DCUN1D1UBE2M
SCHEMBL3408687 0.86 SMN1; SMN2 (0.45) CXCR3EPHX2DCUN1D1UBE2MKMT2A
SCHEMBL3412407 0.86 JAK2 (0.47) EPHX2KMT2AMEN1JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP claimed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A CXCR3 1841/4885CYP2D6 296/4885EPHX2 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.